[1]

Green Z, Ashton JJ, Rodrigues A, et al. Sustained increase in pediatric inflammatory bowel disease incidence across the South West United Kingdom over the last 10 years[J]. Inflamm Bowel Dis, 2024, 30(12): 2271-2279. DOI: 10.1093/ibd/izad302 . https://www.ncbi.nlm.nih.gov/pubmed/38372691 Cited in this article [1]

[2]	官德秀, 吴捷, 张晶, 等. 儿童溃疡性结肠炎临床特征及早期复发危险因素分析[J]. 中华儿科杂志, 2022, 60(7): 660-665. DOI: 10.3760/cma.j.cn112140-20220401-00271 . https://www.ncbi.nlm.nih.gov/pubmed/35768353 Cited in this article [1]

[3]	Moran CJ, Walters TD, Guo CH, et al. IL-10R polymorphisms are associated with very-early-onset ulcerative colitis[J]. Inflamm Bowel Dis, 2013, 19(1): 115-123. PMCID: PMC3744177. DOI: 10.1002/ibd.22974 . https://www.ncbi.nlm.nih.gov/pubmed/22550014 Cited in this article [1]

[4]	Assa A, Rinawi F, Shamir R. The Long-term predictive properties of the Paris classification in paediatric inflammatory bowel disease patients[J]. J Crohns Colitis, 2018, 12(1): 39-47. DOI: 10.1093/ecco-jcc/jjx125 . https://www.ncbi.nlm.nih.gov/pubmed/28961726 Cited in this article [1]

[5]

Cameron FL, Altowati MA, Rogers P, et al. Disease status and pubertal stage predict improved growth in antitumor necrosis factor therapy for pediatric inflammatory bowel disease[J]. J Pediatr Gastroenterol Nutr, 2017, 64(1): 47-55. DOI: 10.1097/MPG.0000000000001379 . https://www.ncbi.nlm.nih.gov/pubmed/27657882 Cited in this article [2]

[6]

Klomberg RCW, van der Wal HC, Aardoom MA, et al. Improved clinical outcomes with early anti-tumour necrosis factor alpha therapy in children with newly diagnosed Crohn's disease: real-world data from the international prospective PIBD-SETQuality inception cohort study[J]. J Crohns Colitis, 2024, 18(5): 738-750. PMCID: PMC11140629. DOI: 10.1093/ecco-jcc/jjad197 . https://www.ncbi.nlm.nih.gov/pubmed/38011797 Cited in this article [1]

[7]

Yerushalmy-Feler A, Olbjorn C, Kolho KL, et al. Dual biologic or small molecule therapy in refractory pediatric inflammatory bowel disease (DOUBLE-PIBD): a multicenter study from the pediatric IBD Porto group of ESPGHAN[J]. Inflamm Bowel Dis, 2024, 30(2): 159-166. DOI: 10.1093/ibd/izad064 . https://www.ncbi.nlm.nih.gov/pubmed/37042978 Cited in this article [3]

[8]	Villanacci V, Alvisi P, Del Sordo R, et al. The histopathology of very early onset-IBD[J]. Dig Liver Dis, 2024, 56(8): 1408-1409. DOI: 10.1016/j.dld.2024.04.020 . https://www.ncbi.nlm.nih.gov/pubmed/38719629 Cited in this article [1]

[9]

Lee WS, Arai K, Alex G, et al. Medical management of pediatric inflammatory bowel disease (PIBD) in the Asia pacific region: a position paper by the Asian Pan-Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD working group[J]. J Gastroenterol Hepatol, 2023, 38(4): 523-538. DOI: 10.1111/jgh.16097 . https://www.ncbi.nlm.nih.gov/pubmed/36574956 Cited in this article [1]

[10]	Schwerd T. Inflammatory bowel diseases in children and adolescents : an overview with particular attention to genetic testing[J]. Inn Med (Heidelb), 2025, 66(1): 31-39. DOI: 10.1007/s00108-024-01827-8 . https://www.ncbi.nlm.nih.gov/pubmed/39774688 Cited in this article [2]

[11]

van Hoeve K, Seyed Tabib NS, Dreesen E, et al. Infliximab concentrations during induction are predictive for endoscopic remission in pediatric patients with inflammatory bowel disease under combination therapy[J]. J Pediatr, 2022, 240: 150-157.e4. DOI: 10.1016/j.jpeds.2021.08.079 . https://www.ncbi.nlm.nih.gov/pubmed/34481805 Cited in this article [3]

[12]	Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease[J]. Gastroenterology, 2015, 148(7): 1320-9.e3. DOI: 10.1053/j.gastro.2015.02.031 . https://www.ncbi.nlm.nih.gov/pubmed/25724455 Cited in this article [4]

[13]

Hoelz H, Bragagna L, Litwin A, et al. Pediatric IBD patients treated with infliximab and proactive drug monitoring benefit from early concomitant immunomodulatory therapy: a retrospective analysis of a 10-year real-life cohort[J]. Inflamm Bowel Dis, 2024, 30(11): 2004-2018. DOI: 10.1093/ibd/izad277 . https://www.ncbi.nlm.nih.gov/pubmed/38011813 Cited in this article [1]

[14]	Jongsma MME, Winter DA, Huynh HQ, et al. Infliximab in young paediatric IBD patients: it is all about the dosing[J]. Eur J Pediatr, 2020, 179(12): 1935-1944. PMCID: PMC7666662. DOI: 10.1007/s00431-020-03750-0 . https://www.ncbi.nlm.nih.gov/pubmed/32813123 Cited in this article [2]

[15]

Lee WS, Chew KS, Huang JG, et al. Disease phenotypic and outcome of very-early onset inflammatory bowel disease in Asian children: an understudied population[J]. Front Pediatr, 2025, 13: 1487253. PMCID: PMC11882516. DOI: 10.3389/fped.2025.1487253 . https://www.ncbi.nlm.nih.gov/pubmed/40051907 Cited in this article [1]

[16]

Toussi SS, Pan N, Walters HM, et al. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature[J]. Clin Infect Dis, 2013, 57(9): 1318-1330. PMCID: PMC3888230. DOI: 10.1093/cid/cit489 . https://www.ncbi.nlm.nih.gov/pubmed/23899685 Cited in this article [1]

[17]	Courbette O, Aupiais C, Viala J, et al. Infliximab paradoxical psoriasis in a cohort of children with inflammatory bowel disease[J]. J Pediatr Gastroenterol Nutr, 2019, 69(2): 189-193. DOI: 10.1097/MPG.0000000000002349 . https://www.ncbi.nlm.nih.gov/pubmed/30921262 Cited in this article [1]

[18]	Cameron FL, Wilson ML, Basheer N, et al. Anti-TNF therapy for paediatric IBD: the Scottish national experience[J]. Arch Dis Child, 2015, 100(4): 399-405. DOI: 10.1136/archdischild-2013-305812 . https://www.ncbi.nlm.nih.gov/pubmed/25678594 Cited in this article [2]

[19]

Patel H, Karam L, Kellermayer R. A single-center study of long-term effectiveness of vedolizumab in anti-TNF refractory pediatric inflammatory bowel disease[J]. JPGN Rep, 2023, 4(1): e276. PMCID: PMC10004749. DOI: 10.1097/PG9.0000000000000276 . https://www.ncbi.nlm.nih.gov/pubmed/36915867 Cited in this article [1]

[20]	Räisänen L, Nikkonen A, Kolho KL. Liver enzyme profiles after initiating biological treatment in children with inflammatory bowel diseases[J]. J Pediatr Gastroenterol Nutr, 2024, 79(3): 583-591. DOI: 10.1002/jpn3.12300 . https://www.ncbi.nlm.nih.gov/pubmed/38946705 Cited in this article [1]

[21]	Hradsky O, Kazeka D, Copova I, et al. Risk factors for dermatological complications of anti-TNF therapy in a cohort of children with Crohn's disease[J]. Eur J Pediatr, 2021, 180(9): 3001-3008. DOI: 10.1007/s00431-021-04077-0 . https://www.ncbi.nlm.nih.gov/pubmed/33876264 Cited in this article [1]

[22]	Conrad MA, Kelsen JR. The treatment of pediatric inflammatory bowel disease with biologic therapies[J]. Curr Gastroenterol Rep, 2020, 22(8): 36. PMCID: PMC8094805. DOI: 10.1007/s11894-020-00773-3 . https://www.ncbi.nlm.nih.gov/pubmed/32542562 Cited in this article [1]

[23]

Burgess CJ, Jackson R, Chalmers I, et al. The inexorable increase of biologic exposure in paediatric inflammatory bowel disease: a Scottish, population-based, longitudinal study[J]. Aliment Pharmacol Ther, 2022, 56(10): 1453-1459. PMCID: PMC9828169. DOI: 10.1111/apt.17217 . https://www.ncbi.nlm.nih.gov/pubmed/36196524 Cited in this article [1]

[24]

Hemming-Harlo M, Merras-Salmio L, Nikkonen A, et al. Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting[J]. Eur J Pediatr, 2024, 183(1): 313-322. PMCID: PMC10858127. DOI: 10.1007/s00431-023-05255-y . https://www.ncbi.nlm.nih.gov/pubmed/37878072 Cited in this article [1]

[25]	Wang Z, Tian L, Jiang Y, et al. Synergistic role of gut-microbial L-ornithine in enhancing ustekinumab efficacy for Crohn's disease[J]. Cell Metab, 2025, 37(5): 1089-1102.e7. DOI: 10.1016/j.cmet.2025.01.007 . https://www.ncbi.nlm.nih.gov/pubmed/39978335 Cited in this article [1]

[26]	Privitera G, Bezzio C, Dal Buono A, et al. How comparative studies can inform treatment decisions for Crohn's disease[J]. Expert Opin Biol Ther, 2024, 24(9): 955-972. DOI: 10.1080/14712598.2024.2389985 . https://www.ncbi.nlm.nih.gov/pubmed/39132872 Cited in this article [2]

[27]

Pujol-Muncunill G, Navas-López VM, Ledder O, et al. STEP-CD study: ustekinumab use in paediatric Crohn's disease-a multicentre retrospective study from paediatric IBD Porto group of ESPGHAN[J]. Eur J Pediatr, 2024, 183(8): 3253-3262. DOI: 10.1007/s00431-024-05588-2 . https://www.ncbi.nlm.nih.gov/pubmed/38700692 Cited in this article [1]

[28]

Rébus S, Coopman S, Djeddi D, et al. Efficacy of vedolizumab and ustekinumab in pediatric-onset inflammatory bowel disease: a real-world multicenter study[J]. J Pediatr Gastroenterol Nutr, 2025, 80(1): 113-123. DOI: 10.1002/jpn3.12384 . https://www.ncbi.nlm.nih.gov/pubmed/39415517 Cited in this article [1]

[29]

Chaemsupaphan T, Leong RW, Vande Casteele N, et al. Review article: optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2024, 60(9): 1234-1243. DOI: 10.1111/apt.18228 . https://www.ncbi.nlm.nih.gov/pubmed/39403056 Cited in this article [1]

[30]

Porth R, Deyhim T, Zullow S, et al. Proactive therapeutic drug monitoring is associated with increased drug persistence in patients with inflammatory bowel disease treated with intravenous vedolizumab[J]. Inflamm Bowel Dis, 2025, 31(2): 485-491. DOI: 10.1093/ibd/izae140 . https://www.ncbi.nlm.nih.gov/pubmed/38953651 Cited in this article [1]

[31]

Vermeire S, Dubinsky MC, Rabizadeh S, et al. Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease[J]. Clin Res Hepatol Gastroenterol, 2024, 48(6): 102374. DOI: 10.1016/j.clinre.2024.102374 . https://www.ncbi.nlm.nih.gov/pubmed/38750934 Cited in this article [1]

[32]

Bonazzi E, Maniero D, Lorenzon G, et al. Comparing point-of-care technology to ELISA testing for infliximab and adalimumab levels in adult inflammatory bowel disease patients: a prospective pilot study[J]. Diagnostics (Basel), 2024, 14(19): 2140. PMCID: PMC11482612. DOI: 10.3390/diagnostics14192140 . https://www.ncbi.nlm.nih.gov/pubmed/39410544 Cited in this article [1]

[33]

Martínez-Pradeda A, Elberdín L, Porta-Sánchez Á, et al. Observational study to compare biological drug concentration quantification techniques and immunogenicity in patients with immune-mediated diseases[J]. Biomedicines, 2024, 12(4): 839. PMCID: PMC11048504. DOI: 10.3390/biomedicines12040839 . https://www.ncbi.nlm.nih.gov/pubmed/38672193 Cited in this article [2]

[34]

Wu JJ, Lin L, Yan JJ, et al. Development and validation of a sensitive LC-MS/MS assay for determination of upadacitinib in human plasma and its application in patients with inflammatory bowel disease[J]. J Pharmacol Toxicol Methods, 2025, 131: 107581. DOI: 10.1016/j.vascn.2025.107581 . https://www.ncbi.nlm.nih.gov/pubmed/39862900 Cited in this article [1]

[35]

Bouhuys M, Wessels MMS, de Vries W, et al. Lateral flow test versus enzyme-linked immunosorbent assay to measure infliximab trough concentrations: a head-to-head comparison[J]. J Pediatr Gastroenterol Nutr, 2024, 79(6): 1134-1141. PMCID: PMC11615136. DOI: 10.1002/jpn3.12372 . https://www.ncbi.nlm.nih.gov/pubmed/39390697 Cited in this article [1]

[36]	Shmais M, Regueiro M, Hashash JG. Proactive versus reactive therapeutic drug monitoring: why, when, and how?[J]. Inflamm Intest Dis, 2022, 7(1): 50-58. PMCID: PMC8820143. DOI: 10.1159/000518755 . https://www.ncbi.nlm.nih.gov/pubmed/35224018 Cited in this article [1]

[37]

Farber M, Polman J, Kohn N, et al. A Real-World comparison of drug trough levels between patients experiencing a secondary nonimmune loss of response and those maintaining a response to infliximab on long-term maintenance therapy for inflammatory bowel disease[J]. Inflamm Intest Dis, 2024, 9(1): 252-259. PMCID: PMC11521506. DOI: 10.1159/000541377 . https://www.ncbi.nlm.nih.gov/pubmed/39474329 Cited in this article [1]

[38]

Marquez-Megias S, Nalda-Molina R, Sanz-Valero J, et al. Cost-effectiveness of therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease: a systematic review[J]. Pharmaceutics, 2022, 14(5): 1009. PMCID: PMC9145467. DOI: 10.3390/pharmaceutics14051009 . https://www.ncbi.nlm.nih.gov/pubmed/35631594 Cited in this article [2]

[39]

Guidi L, Pugliese D, Panici Tonucci T, et al. Therapeutic drug monitoring is more cost-effective than a clinically based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multicentre study[J]. J Crohns Colitis, 2018, 12(9): 1079-1088. DOI: 10.1093/ecco-jcc/jjy076 . https://www.ncbi.nlm.nih.gov/pubmed/29860436 Cited in this article [1]

[40]

Kang B, Choi SY, Choi YO, et al. Infliximab trough levels are associated with mucosal healing during maintenance treatment with infliximab in paediatric Crohn's disease[J]. J Crohns Colitis, 2019, 13(2): 189-197. DOI: 10.1093/ecco-jcc/jjy155 . https://www.ncbi.nlm.nih.gov/pubmed/30452616 Cited in this article [1]

[41]

Papamichael K, Clarke WT, Vande Casteele N, et al. Comparison of assays for therapeutic monitoring of infliximab and adalimumab in patients with inflammatory bowel diseases[J]. Clin Gastroenterol Hepatol, 2021, 19(4): 839-841.e2. PMCID: PMC7483237. DOI: 10.1016/j.cgh.2020.03.002 . https://www.ncbi.nlm.nih.gov/pubmed/32147594 Cited in this article [3]

[42]

Desai DC, Dherai AJ, Strik A, et al. Personalized dosing of infliximab in patients with inflammatory bowel disease using a Bayesian approach: a next step in therapeutic drug monitoring[J]. J Clin Pharmacol, 2023, 63(4): 480-489. DOI: 10.1002/jcph.2189 . https://www.ncbi.nlm.nih.gov/pubmed/36458468 Cited in this article [2]

[43]

Sánchez-Hernández JG, Rebollo N, Martin-Suarez A, et al. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease[J]. Br J Clin Pharmacol, 2020, 86(6): 1165-1175. PMCID: PMC7256129. DOI: 10.1111/bcp.14229 . https://www.ncbi.nlm.nih.gov/pubmed/32022291 Cited in this article [1]

[44]

Strik AS, Löwenberg M, Mould DR, et al. Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial[J]. Scand J Gastroenterol, 2021, 56(2): 145-154. DOI: 10.1080/00365521.2020.1856405 . https://www.ncbi.nlm.nih.gov/pubmed/33290108 Cited in this article [1]

[45]

Ventin-Holmberg R, Höyhtyä M, Saqib S, et al. The gut fungal and bacterial microbiota in pediatric patients with inflammatory bowel disease introduced to treatment with anti-tumor necrosis factor-α[J]. Sci Rep, 2022, 12(1): 6654. PMCID: PMC9033777. DOI: 10.1038/s41598-022-10548-7 . https://www.ncbi.nlm.nih.gov/pubmed/35459927 Cited in this article [2]

[46]

Marković S, Kralj Đ, Svorcan P, et al. Vedolizumab clearance as a surrogate marker for remission in inflammatory bowel disease patients: insights from real-world pharmacokinetics[J]. Pharmaceutics, 2024, 16(12): 1629. PMCID: PMC11677246. DOI: 10.3390/pharmaceutics16121629 . https://www.ncbi.nlm.nih.gov/pubmed/39771608 Cited in this article [1]

[47]

Hüttemann E, Muzalyova A, Gröhl K, et al. Efficacy and safety of vedolizumab in patients with inflammatory bowel disease in association with vedolizumab drug levels[J]. J Clin Med, 2023, 13(1): 140. PMCID: PMC10779856. DOI: 10.3390/jcm13010140 . https://www.ncbi.nlm.nih.gov/pubmed/38202147 Cited in this article [2]

[48]	Saleh A, Stading R, Miroballi N, et al. Therapeutic drug monitoring in patients with inflammatory bowel disease on ustekinumab[J]. J Dig Dis, 2024, 25(4): 214-221. DOI: 10.1111/1751-2980.13264 . https://www.ncbi.nlm.nih.gov/pubmed/38587053

[49]

SaYao JY, Zhang M, Wang W, et al.. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study[J]. BMC Gastroenterol, 2021, 21(1): 380. PMCID: PMC8522105. DOI: 10.1186/s12876-021-01946-8 . https://www.ncbi.nlm.nih.gov/pubmed/34663208 Cited in this article [1]

[50]

Porth R, Deyhim T, Geeganage G, et al. Proactive therapeutic drug monitoring of ustekinumab is associated with increased drug persistence in patients with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2025, 31(7): 1806-1810. DOI: 10.1093/ibd/izae231 . https://www.ncbi.nlm.nih.gov/pubmed/39326011 Cited in this article [1]